SCHEMBL4440360

SCHEMBL4440360

CN(c1cc(C=O)ccc1F)S(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
PARP1 P09874 1/20 0.41
AKR1B1 P15121 1/20 0.38
KMT2A Q03164 2/20 0.38
CYP2A6 P11509 1/20 0.36
CYP2A13 Q16696 1/20 0.36
ALDH1A1 P00352 5/20 0.35
ALDH1A3 P47895 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP19A1 P11511 3/20 0.33
ALDH3A1 P30838 2/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
TSHR P16473 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20529121 0.80 CYP2A6 (0.47) KMT2ACYP2A6CYP2A13ALDH1A1ALDH1A3
SCHEMBL20092189 0.80 CYP2A6 (0.36) KMT2ACYP2A6CYP2A13ALDH1A1ALDH1A3
SCHEMBL3253845 0.72 KMT2A (0.45) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7754930 0.72 PTGS2 (0.39) CYP2A6ALDH1A1SMN1; SMN2TSHRPTGS2
SCHEMBL26519237 0.71 KMT2A (0.50) KMT2AALDH1A1CYP19A1ALOX5APFEN1
SCHEMBL30005025 0.70 KMT2A (0.61) KMT2AALDH1A1SMN1; SMN2TSHRPTGS2
SCHEMBL3186339 0.69 CYP2A6 (0.47) CYP2A6CYP2A13ALDH1A1ALDH1A3SMN1; SMN2
SCHEMBL2106816 0.69 CYP1A2 (0.54) KMT2AALDH1A1SMN1; SMN2
SCHEMBL5713783 0.69 ALDH1A1 (0.48) KMT2AALDH1A1SMN1; SMN2
SCHEMBL29399275 0.68 ALDH1A1 (0.42) CYP2A6ALDH1A1SMN1; SMN2TSHRPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9283222-B2 Inhibitors of poly(ADP-ribose)polymerase ABBVIE INC. (US) 2016-03-15 US disclosed
EP-2698062-B1 Inhibitors of poly(adp-ribose)polymerase ABBVIE INC (US) 2015-06-24 EP disclosed
US-20140212509-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBVIE INC. (US) 2014-07-31 US disclosed
EP-2698062-A1 Inhibitors of poly(adp-ribose)polymerase Abbvie Inc. (US) 2014-02-19 EP disclosed
EP-2120579-B1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBVIE INC (US) 2013-11-13 EP disclosed
US-8466150-B2 Inhibitors of poly(ADP-ribose)polymerase ABBOTT LABORATORIES (US) 2013-06-18 US disclosed
EP-2120579-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBOTT LABORATORIES (US) 2009-11-25 EP disclosed
US-20080269234-A1 Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents ABBOTT LABORATORIES (US) 2008-10-30 US disclosed
WO-2008083027-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBOTT LABORATORIES (US) 2008-07-10 WO disclosed
US-20080161280-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBOTT LABORATORIES (US) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269234-A1 Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents PARP1, DPYD, PARP2 PSEN1 4278/4885PSEN2 4196/4885APH1B 3271/4885
US-20140212509-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP3 PSEN1 3826/4885PSEN2 3402/4885APH1B 2004/4885
US-20080161280-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP3 PSEN1 3826/4885PSEN2 3402/4885APH1B 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.